Novavax Inc (Novavax) is a biotechnology company that discovers, develops and commercializes vaccines to prevent a wide range of infectious diseases. The company develops genetically-engineered vaccine candidates harnessing three-dimensional nanostructures of recombinant proteins critical to disease pathogenesis. Its pipeline products include NVX-CoV2373 for coronavirus, NanoFlu for seasonal influenza, ResVax for respiratory syncytial syndrome and vaccines indicated for the prevention of Ebola virus, Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS). It is also developing proprietary immune-stimulating saponin-based adjuvants. The company operates research and manufacturing facilities in Gaithersburg, Maryland; Uppsala, Sweden; and Bohumil, Czech Republic. Novavax is headquartered in Gaithersburg, Maryland, the US.

Headquarters United States of America

Address 21 Firstfield Road, Gaithersburg, Maryland, 20878


Telephone 1 240 2682000

No of Employees 1,541

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange NVAX (NASD)

Revenue (2022) $1.1B 141% (2022 vs 2021)

EPS XXX

Net Income (2022) XXX -316.9% (2022 vs 2021)

Market Cap* $1.0B

Net Profit Margin (2022) XXX -73.0% (2022 vs 2021)

* As of and is in US$

Access premium data and analytics for Novavax Inc

100+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Novavax Inc’s relevant decision makers and contact details.

70+

Catalyst Calendar

Proactively evaluate Novavax Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

70+

Clinical Trials

Determine Novavax Inc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

30+

Pipeline Drugs

Identify which of Novavax Inc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

20+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

4

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

1

Marketed Drugs

Understand Novavax Inc’s commercialized product portfolio to stay one step ahead of the market.

110+

Install Base

Install Base provides a holistic and a granular view of the IT product/service deployments from leading vendors. Explore IT infrastructure categories, solution and product/service areas deployed by a prospect.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Novavax Inc’s likely spend across technology areas enabling you to understand the digital strategy.

Subscribe to Company Analytics & gain access to premium industry data & analytics Subscribe to Company Analytics & gain access to premium industry data & analytics Start Here

Products and Services

Products Brands
Pipeline NanoFlu
NVX-CoV2373 – Coronavirus Matrix-M
NanoFlu - Seasonal Influenza Vaccine ResVax
XXX
XXX
XXX
Subscribe to Company Analytics for access to more products & services data Subscribe to Company Analytics for access to more products & services data Learn More

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2022 Regulatory Approval In December, the company announced Health Canada approved a supplement to a New Drug Submission (sNDS) for Nuvaxovid (COVID-19 Vaccine (Recombinant protein, Adjuvanted)) (NVX-CoV2373).
2022 Regulatory Approval In July, the company received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) to provide a two-dose primary series for active immunization to prevent coronavirus disease 2019.
2022 Others In May, the company announced the initiation of its Phase 3 strain change trial to determine if its Omicron variant specific vaccine, NVX-CoV2515.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Get Started
Image for loader

Competitor Comparison

Key Parameters Novavax Inc Novartis AG Merck & Co Inc GSK plc AstraZeneca Plc
Headquarters United States of America Switzerland United States of America United Kingdom United Kingdom
City Gaithersburg Basel Kenilworth Brentford Cambridge
State/Province Maryland - New Jersey - Cambridgeshire
No. of Employees 1,541 108,000 68,000 90,096 83,100
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
James F. Young, Ph.D. Chairman Executive Board 2011 69
John Jacobs Chief Executive Officer; Director; President Executive Board 2023 -
Jim Kelly Treasurer; Executive Vice President; Chief Financial Officer Senior Management 2021 56
Rick Crowley Executive Vice President; Chief Operating Officer Senior Management 2020 -
Biegie Lee Senior Vice President; Chief Information Officer Senior Management 2020 -
Non Dignissim Eros Proin vel Convallis 2023 XX
Non Dignissim Eros Proin vel Convallis 2023 XX
Non Dignissim Eros Proin vel Convallis 2023 XX
Gain more insight into company management & employee structure with Company Analytics Gain more insight into company management & employee structure with Company Analytics Subscribe
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company Analytics

Contact the team or request a demo to find out how our data can drive your business forward

Why are you leaving?